Key Highlights:
- Bristol-Myers Squibb beats earnings expectations with a Non-GAAP EPS of $1.80.
- The company's revenue reached $11.2 billion, surpassing forecasts by $490 million.
- Future projections suggest significant growth potential with a 30.02% upside according to GF Value estimates.
Bristol-Myers Squibb Co. (BMY, Financial) has delivered impressive first-quarter earnings, showcasing a Non-GAAP EPS of $1.80 that exceeded analysts' expectations by $0.30. Despite a 6% decline year-over-year, the company's revenue hit $11.2 billion, outpacing estimates by $490 million. Looking ahead, Bristol-Myers Squibb forecasts 2025 revenue to range from $45.5 billion to $46.8 billion, with EPS estimated between $6.70 and $7.00.
Wall Street Analysts Forecast
According to projections from 22 analysts, the average one-year price target for Bristol-Myers Squibb Co (BMY, Financial) is $56.89, with estimates ranging from a high of $70.00 to a low of $33.10. This average target suggests a potential upside of 17.22% from the current share price of $48.53. For more in-depth analysis, investors can refer to the Bristol-Myers Squibb Co (BMY) Forecast page.
The consensus recommendation from 28 brokerage firms positions Bristol-Myers Squibb Co (BMY, Financial) with an average recommendation of 2.7, categorizing it under "Hold." The recommendation scale spans from 1 to 5, with 1 implying a Strong Buy and 5 indicating a Sell.
Leveraging GuruFocus' proprietary metrics, the estimated GF Value for Bristol-Myers Squibb Co (BMY, Financial) in one year is $63.10. This estimation suggests a notable upside of 30.02% from the current price of $48.53. The GF Value is a calculated fair value based on historical trading multiples, past business growth, and projected business performance. Investors seeking detailed insights can visit the Bristol-Myers Squibb Co (BMY) Summary page.
